Pages that link to "Q38959812"

The following pages link to Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. (Q38959812):

Displaying 17 items.

• Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies (Q28395597) (← links)
• Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. (Q37457703) (← links)
• Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer (Q37688471) (← links)
• The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells (Q42038363) (← links)
• FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. (Q47160915) (← links)
• A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. (Q47162061) (← links)
• Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. (Q48521717) (← links)
• Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications (Q49996923) (← links)
• Radiotherapy for the treatment of malignant pleural mesothelioma (Q50200696) (← links)
• Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074 (Q60907702) (← links)
• Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity (Q90133145) (← links)
• The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma (Q90418443) (← links)
• Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer (Q90461777) (← links)
• Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial (Q92134619) (← links)
• The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy (Q92190778) (← links)
• Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors (Q92705359) (← links)
• Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Q98386378) (← links)